New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
08:08 EDTHRTXHeron Therapeutics reports Q2 EPS (78c), consensus (74c)
The company said, "The increase in net loss was primarily due to the initiation of a Phase 3 label expansion study of SUSTOL in Q1 and expenses related to new product development, including our new program targeting the relief of post-surgical pain, which was initiated in November 2013."
News For HRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for HRTX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use